Glucocorticoid Receptor 

 186 Products   186 Products   1696 Diseases   95004 News 


«12...177178179180181182183184185186187...10651066»
  • ||||||||||  tasquinimod (ABR-215050) / Active Biotech, Ipsen
    Trial completion date, Trial primary completion date, Combination therapy:  Tasquinimod for the Treatment of Relapsed or Refractory Myeloma (clinicaltrials.gov) -  Apr 14, 2023   
    P1,  N=34, Recruiting, 
    Trial completion date: Jun 2024 --> Dec 2024 | Trial primary completion date: Jun 2023 --> Dec 2023
  • ||||||||||  Decadron (dexamethasone) / Merck (MSD)
    Trial completion date:  Carfilzomib, Clarithromycin (Biaxin (clinicaltrials.gov) -  Apr 14, 2023   
    P2,  N=74, Active, not recruiting, 
    Trial completion date: Jun 2024 --> Dec 2024 | Trial primary completion date: Jun 2023 --> Dec 2023 Trial completion date: Mar 2023 --> Mar 2024
  • ||||||||||  Sarclisa (isatuximab-irfc) / Sanofi
    Enrollment closed, Enrollment change, Trial completion date, Trial primary completion date:  Isatuximab, Bendamustine, and Prednisone in Refractory Multiple Myeloma (clinicaltrials.gov) -  Apr 14, 2023   
    P1/2,  N=15, Active, not recruiting, 
    Trial completion date: Mar 2023 --> Mar 2024 Recruiting --> Active, not recruiting | N=37 --> 15 | Trial completion date: Oct 2029 --> Dec 2023 | Trial primary completion date: Oct 2024 --> Mar 2023
  • ||||||||||  dexamethasone / Generic mfg.
    Journal:  A cosmetic complication after supraorbital/supratrochlear nerve block. (Pubmed Central) -  Apr 14, 2023   
    Based on this study, we propose a LNSC cutoff ?6.73 nmol/L to diagnose CS. In this article, a cosmetic complication case secondary to bilateral supraorbital and supratrochlear nerve block with low dose local anesthetic and dexamethasone combination is presented.
  • ||||||||||  Review, Journal:  Pharmacological Modulation of Temporal Discounting: A Systematic Review. (Pubmed Central) -  Apr 13, 2023   
    Thus, it can be concluded that dopamine is a crucial modulator for temporal discounting, especially the D2 receptor, and cortisol also has an important time-dependent role in this type of decision. One of the limitations of this systematic review is the heterogeneity of the drugs used to assess the effect of temporal discounting.
  • ||||||||||  Ninlaro (ixazomib) / Takeda
    Review, Journal:  30 Years of Improved Survival in Non-Transplant-Eligible Newly Diagnosed Multiple Myeloma. (Pubmed Central) -  Apr 13, 2023   
    However, progress is still expected with the introduction in the armamentarium for NTE patients of the most recent innovative immunotherapy-based treatments newly introduced in MM, e.g., CAR-T cells and bispecific antibodies. These "improved versions" of immune-based treatments will probably also benefit NTE patients, although further studies will be needed to better understand their role in this population.
  • ||||||||||  hydrocortisone / Generic mfg.
    Enrollment change, Trial completion date, Trial withdrawal, Trial primary completion date:  TSM-1: rTMS of Limbic Circuitry in Stress Modulation in Healthy Volunteers (clinicaltrials.gov) -  Apr 13, 2023   
    P2,  N=0, Withdrawn, 
    Trial completion date: Oct 2022 --> Oct 2024 | Trial primary completion date: Oct 2022 --> Oct 2024 N=20 --> 0 | Trial completion date: Dec 2023 --> Apr 2023 | Not yet recruiting --> Withdrawn | Trial primary completion date: Oct 2023 --> Apr 2023
  • ||||||||||  hydrocortisone / Generic mfg.
    Enrollment change, Trial completion date, Trial withdrawal, Trial primary completion date:  OTC-1: Using rTMS to Explore Neural Mechanisms of Stress-Induced Opioid Use (clinicaltrials.gov) -  Apr 13, 2023   
    P2,  N=0, Withdrawn, 
    N=20 --> 0 | Trial completion date: Dec 2023 --> Apr 2023 | Not yet recruiting --> Withdrawn | Trial primary completion date: Oct 2023 --> Apr 2023 N=32 --> 0 | Trial completion date: Jun 2025 --> Apr 2023 | Not yet recruiting --> Withdrawn | Trial primary completion date: Oct 2023 --> Apr 2023
  • ||||||||||  dexamethasone / Generic mfg., azathioprine / Generic mfg.
    Preclinical, Journal:  Therapeutic approaches for anti-sperm-antibodies in the testicular sperm aspiration rat model. (Pubmed Central) -  Apr 12, 2023   
    Tissue samples from the secondary antibody-treated rats showed a generally normal histological appearance. This study tried to offer realistic therapy suggestions; however, caution should be applied when extrapolating findings from experimental models to meet clinical requirements.
  • ||||||||||  dexamethasone / Generic mfg.
    Autophagy regulates the generation and differentiation of chemically derived hepatic progenitors (CdHs) (Poster Area) -  Apr 12, 2023 - Abstract #EASLILC2023EASL_ILC_2198;    
    In conclusion, all these findings indicate that autophagy regulates the generation of CdHs and the differentiation of CdHs into CdH-Heps. This research was supported by the National Research Foundation of Korea (2022R1A2C2004593), and the Korean Fund for Regenerative Medicine funded by Ministry of Science and ICT, and Ministry of Health and Welfare (21A0401L1).
  • ||||||||||  Control compounds used to validate in vitro models of idiosyncratic drug-induced liver injury: a systematic review (Poster Area) -  Apr 12, 2023 - Abstract #EASLILC2023EASL_ILC_955;    
    Since no single system serves as a universal test for the multifactorial process of DILI, a portfolio of robust and well-characterized predictive platforms with a well-defined purpose is required. Moreover, there is a need for consensus about the reference drugs to be used for the DILI assay validations, including recommendations about the concentrations to test and criteria for interpreting the data.
  • ||||||||||  dexamethasone / Generic mfg.
    Trial completion date, Trial primary completion date:  Individualizing Corticosteroid Use in Pneumonia (clinicaltrials.gov) -  Apr 12, 2023   
    P2,  N=24, Not yet recruiting, 
    This trial is registered in the Thai Clinical Trials Registry (TCTR20220318004; date of registration, March 17, 2022). Trial completion date: Jul 2025 --> Dec 2026 | Trial primary completion date: Jul 2025 --> Dec 2026
  • ||||||||||  dexamethasone / Generic mfg.
    Trial completion date, Trial primary completion date, Surgery:  SURTHODEX: DEXAMETHASONE for Non-urgent Thoracic Surgery (clinicaltrials.gov) -  Apr 12, 2023   
    P=N/A,  N=1600, Recruiting, 
    Trial completion date: Jul 2025 --> Dec 2026 | Trial primary completion date: Jul 2025 --> Dec 2026 Trial completion date: Mar 2023 --> Mar 2024 | Trial primary completion date: Mar 2023 --> Mar 2024
  • ||||||||||  Breztri Aerosphere (budesonide/formoterol fumarate/glycopyrronium) / AstraZeneca, budesonide/formoterol (PT009) / AstraZeneca
    Trial completion date, Trial primary completion date:  Study to Assess PT010 in Adult and Adolescent Participants With Inadequately Controlled Asthma (LOGOS) (clinicaltrials.gov) -  Apr 12, 2023   
    P3,  N=2200, Recruiting, 
    Trial completion date: Dec 2022 --> Feb 2024 | Trial primary completion date: Dec 2022 --> Jan 2024 Trial completion date: Mar 2024 --> Mar 2025 | Trial primary completion date: Mar 2024 --> Mar 2025
  • ||||||||||  Trial completion date, Trial primary completion date:  Effects of Pharmacological Stress and RTMS on Executive Function in Opioid Use Disorder (clinicaltrials.gov) -  Apr 12, 2023   
    P2,  N=20, Not yet recruiting, 
    Trial completion date: Mar 2024 --> Mar 2025 | Trial primary completion date: Mar 2024 --> Mar 2025 Trial completion date: Dec 2023 --> Dec 2025 | Trial primary completion date: Oct 2023 --> Oct 2025
  • ||||||||||  dexamethasone / Generic mfg.
    Going oversized: Testing the limits of endogenous thymic regeneration and uncovering the mechanisms of thymic hypertrophy. (P346) (Exhibit Hall; Poster Board No. P346) -  Apr 11, 2023 - Abstract #IMMUNOLOGY2023IMMUNOLOGY_1410;    
    Moreover, we also found that unlike injury from ionizing radiation, Dexamethasone (Dex) mediated damage led to thymic hypertrophy...We will test our hypothesis through genetic mouse models, cytokine modulation, and standard immunophenotyping. The positive results of this study will augment our basic knowledge of the endogenous mechanisms of thymic regeneration and inform the creation of thymic boosting therapies.
  • ||||||||||  dexamethasone / Generic mfg.
    Paradoxically Increased Inflammation in Immunosuppressed Individuals with COVID-19 (P616) (Exhibit Hall; Poster Board No. P616) -  Apr 11, 2023 - Abstract #IMMUNOLOGY2023IMMUNOLOGY_1134;    
    Treatment with dexamethasone and IL-6 blockade can be life-saving in patients stratified for moderate - severe disease...In support of our hypothesis, we found that immunosuppressed individuals had higher levels of the inflammatory cytokines IP-10 (p=0.03) and MCP-1 (p=0.01) compared to immunocompetent patients matched for COVID-19 severity. This suggests that immunosuppressed patients may benefit as much as immunocompetent individuals from systemic treatments to dampen inflammation in COVID-19, and current recommendations of excluding these patients from treatment solely on the basis of immune competence may need to be re-evaluated.
  • ||||||||||  dexamethasone / Generic mfg.
    Social Status is Associated with Impaired Anti-Inflammatory Response in Free-Ranging Male Rhesus Macaques (P940) (Exhibit Hall; Poster Board No. P940) -  Apr 11, 2023 - Abstract #IMMUNOLOGY2023IMMUNOLOGY_598;    
    We stimulated peripheral blood mononuclear cells (PBMCs) in vitro with Dexamethasone (Dex), an anti-inflammatory synthetic glucocorticoid (GC), and measured how social status influenced the gene regulatory response to Dex stimulation using mRNA-seq...For instance, low social status animals had significantly higher expression (FDR<0.2) of signature genes in this pathway including AKT3, MAPK1 and PIK3CD. Our study suggests that the anti-inflammatory immune response in rhesus macaques can be negatively affected by low social status, with animals having a blunted response to Dex and presenting signatures of GC resistance.
  • ||||||||||  dexamethasone / Generic mfg., sirolimus / Generic mfg.
    Complete tolerogenic response adjuvant stimulates Treg response to immunization (P652) (Exhibit Hall; Poster Board No. P652) -  Apr 11, 2023 - Abstract #IMMUNOLOGY2023IMMUNOLOGY_126;    
    Specifically, we are evaluating the tolerogenic efficacy of this adjuvant for vaccination regimen targeting the apolipoprotein B antigen, using the ApoE-/- mouse model of atherosclerosis. These studies are expected to help drive the development of further, perhaps more effective, complete tolerogenic adjuvants that could be used to create a plethora of new, novel vaccines for treating immunological illnesses.
  • ||||||||||  dexamethasone cyclodextrin nanoparticle ophthalmic suspension (OCS-01) / Oculis
    Trial completion date, Trial primary completion date:  LEOPARD: Multicenter Study on the Efficacy and Safety of OCS-01 in Subjects With Uveitis Related and Post Surgical Macular Edema (clinicaltrials.gov) -  Apr 11, 2023   
    P2,  N=24, Not yet recruiting, 
    Any sudden worsening of fundus findings in a patient with diabetes necessitates immediate and detailed ocular and systemic evaluation, especially when the immune status is unknown. Trial completion date: Dec 2023 --> Apr 2024 | Trial primary completion date: Oct 2023 --> Jan 2024
  • ||||||||||  melphalan / Generic mfg.
    Journal, Tumor mutational burden:  High-Dose Melphalan Treatment Significantly Increases Mutational Burden at Relapse in Multiple Myeloma. (Pubmed Central) -  Apr 10, 2023   
    These data provide new hypotheses for mechanisms of action for a subset of PFAS and may further aid in development of a PFAS categorization strategy useful in safety assessment. We performed deep whole-genome sequencing on samples from 68 patients, 43 of whom were treated with RVD (lenalidomide, bortezomib, and dexamethasone) and 25 with RVD
  • ||||||||||  Ninlaro (ixazomib) / Takeda
    Trial completion date, Trial primary completion date, Combination therapy:  Ixazomib With Pomalidomide, Clarithromycin and Dexamethasone in Treating Patients With Multiple Myeloma (clinicaltrials.gov) -  Apr 10, 2023   
    P1/2,  N=30, Active, not recruiting, 
    We performed deep whole-genome sequencing on samples from 68 patients, 43 of whom were treated with RVD (lenalidomide, bortezomib, and dexamethasone) and 25 with RVD Trial completion date: Jun 2023 --> Dec 2023 | Trial primary completion date: Sep 2022 --> Jul 2023
  • ||||||||||  Zilretta (triamcinolone acetonide ER) / Pacira, Monovisc (sodium hyaluronate) / Anika Therap
    Enrollment change, Trial completion date, Trial termination, Trial primary completion date:  Trial Comparing Three Single Dose Injections for Knee Osteoarthritis (clinicaltrials.gov) -  Apr 10, 2023   
    P4,  N=6, Terminated, 
    Potential participants are unwilling to participate in the study due to the randomziation and blinding. Both aspects are needed to ensure a robust comparison between groups.
  • ||||||||||  Fiblast (trafermin) / Kaken Pharma
    Journal:  Evaluation of Safety After Intracordal Basic Fibroblast Growth Factor Injection. (Pubmed Central) -  Apr 8, 2023   
    The results suggest that the early postinjective complications are not due to the drug action of trafermin, but rather to complications from the intracordal injection procedures. Intracordal trafermin injection may be safe in the short term.